Pre-Clinical
AI has accelerated target generation. The bottleneck is now validation: are these targets expressed on the cells that matter, in the patients who need treatment? Our discovery capabilities start where most platforms stop, with single-cell resolution of clinically annotated human tissue.
Features
Semper ac sodales adipiscing
Antibody-Based Target Discovery
Systematically identify surface antigens expressed on malignant cells, and critically, on tumor-initiating cells, using CITE-seq surface protein mapping and functional validation in primary tissue. Every candidate target is linked to longitudinal patient outcomes, so you know not just that a target is present, but whether it’s present on the cells that drive disease progression and relapse.
This is how we built the biological foundation for our AML ADC discovery program, and it’s the same capability available to pharma partners working in any of our active indications.
Antibody-Based Target Discovery
Systematically identify surface antigens expressed on malignant cells, and critically, on tumor-initiating cells, using CITE-seq surface protein mapping and functional validation in primary tissue. Every candidate target is linked to longitudinal patient outcomes, so you know not just that a target is present, but whether it’s present on the cells that drive disease progression and relapse.
This is how we built the biological foundation for our AML ADC discovery program, and it’s the same capability available to pharma partners working in any of our active indications.
Let’s Advance Smarter Drug Development
Whether you are seeking decision-ready insight, structured clinical data collaboration, or joint asset development, RefinedScience partners with teams committed to improving drug development outcomes.